RxDoctor Payments Data

Daisy Matias, MD

Family Medicine · Winfield, KSNPI 1740481290

Payments from drug & device makers

$1,278in general payments, 2019–2025

Across 81 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$220
  • Sanofi-aventis U.S. LLC$197
  • Lilly USA, LLC$156
  • AstraZeneca$155
  • Amgen$125
  • Pfizer$120
  • plus $305 from 13 others

What the payments were for

  • Food & beverage$1,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,278 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$1,277
Medicare patients
64
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$82,112
EliquisApixaban95$55,624
JardianceEmpagliflozin63$51,043
TrulicityDulaglutide23$23,267
MyrbetriqMirabegron21$14,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,825
XareltoRivaroxaban22$14,004
MounjaroTirzepatide13$13,278
Tresiba Flextouch U-200Insulin Degludec14$11,226
Incruse ElliptaUmeclidinium Bromide21$7,616
Tresiba Flextouch U-100Insulin Degludec14$6,219
SymbicortBudesonide/Formoterol Fumarate14$5,275
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$2,995
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,503
Gabapentin198$2,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$220$82,11285 claims
PfizerEliquis$120$55,62495 claims
Boehringer IngelheimJardiance$35$51,04363 claims
Lilly USA, LLCTrulicity, Mounjaro$156$36,54536 claims
Johnson & JohnsonXarelto$42$14,00422 claims
AstraZenecaSymbicort$155$5,27514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Winfield

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →